Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: Treatment up to complete wound closure

International Wound Journal

Volumn 6, Issue 1, 2009, Pages 67-72

  Fernández Montequín, José I ^a   Betancourt, Blas Y ^b   Leyva Gonzalez, Gisselle ^c   Mola, Ernesto L ^d   Galán Naranjo, Katia ^a   Ramírez Navas, Mayte ^a   Bermúdez Rojas, Sergio ^e   Rosales, Felix ^a   García Iglesias, Elizeth ^b   Berlanga Acosta, Jorge ^d   Silva Rodriguez, Ricardo ^d   Garcia Siverio, Marianela ^d   Martinez, Luis H ^d  

^a National Institute of Angiology and Vascular Surgery   (Cuba)

^b Center for Biological Research Cuba   (Cuba)

^c Health Lodging 'Manuel Fajardo' ^*

^d CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^e 'Hermanos Amejeiras' University Hospital   (Cuba)

Author keywords

Diabetic foot ulcers; Epidermal growth factor; Wound healing

Indexed keywords

ANTIBIOTIC AGENT; CHLORHEXIDINE; HEBERPROT P; INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE PAIN; ARTICLE; CHILL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; DISEASE DURATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPOTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SWEATING; TREMOR; ULCER HEALING; UNCONSCIOUSNESS; WEAKNESS; WOUND CARE; WOUND CLOSURE; WOUND INFECTION;

AGED; DIABETIC FOOT; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; EPIDERMAL GROWTH FACTOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; WOUND HEALING;

EID: 61849127890     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/j.1742-481X.2008.00561.x     Document Type: Article

References (24)

1. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV. American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006 45 (5 Suppl S1 S66.
2. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ERE, Whalley AM, Widdows P, Williamson S, Boulton AJM. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002 19 : 377 84.
3. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998 21 : 1071 5.
4. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005 366 : 1719 24.
5. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998 21 : 822 7.
6. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005 13 : 531 6.
7. Veves A, Falanga V, Armstrong DG, Sabolinski ML Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001 24 : 290 5.
8. Marston WA, Hanft J, Norwood P, Pollak R Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003 26 : 1701 5.
9. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. The epidermal growth factor. Cell Biol Int 1995 19 : 413 30.
10. Tsang MW, Wong WKR, Hung CS, Lai KM, Tang W, Cheung EYN, Kam G, Leung L, Chan CW, Chu CM, Lam EKH. Human epidermal growth factor enhances healing of Diabetic foot ulcers. Diabetes Care 2003 26 : 1856 61.
11. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 2006 56 : 394 8.
12. Viswanathan V, Pendsey S, Sekar N, Murthy GSR. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D™ 150) in healing diabetic foot ulcers. Wounds 2006 18 : 186 96.
13. Berlanga J, Lodos J, Reyes O, Infante JF, Caballero E, López-Saura P. Epidermal growth factor stimulated re-epithelialization in pigs. The possible role of acute-wound proteases. Biotecnología Aplicada 1998 15 : 83 7.
14. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999 7 : 442 52.
15. Medina A, Scott PG, Ghahary A, Tredget EE. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil 2005 26 : 306 19.
16. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996 4 : 411 20.
17. Berlanga J, Savigne W, Valdez C, Franco N, Alba JS, Del Rio A, López-Saura P, Guillén G, Lopez E, Herrera L, Férnandez- Montequín J. Epidermal growth factor intra-lesional infiltrations can prevent amputation in diabetic patients with advanced foot ulcers. Int Wound J 2006 3 : 232 9.
18. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutiérrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA, Cuban Citoprot-P Study Group. Intra-lesional injections of Citoprot-P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007 4 : 333 43.
19. Cinza AM, Quintana M, Lombardero J, Poutou R, Pérez E, Pérez LC, Castellanos L, Estrada R, Morales J. A batch process for production of human epidermal growth factor in yeast. Product characterization. Biotecnología Aplicada 1991 8 : 166 74.
20. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect 2004 39 : 885 910.
21. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, Manolas C. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications 2007 21 : 387 91.
22. Falanga V, Eaglstein WH. The trap hypothesis of venous ulceration. Lancet 1993 341 : 1006 8.
23. Robson MC, Smith PD. Topical use of growth factors to enhance healing. In : Falanga V, editor. Cutaneous wound healing. London : Martin Dunitz Limited, 2001 : 379 98.
24. Guidance for industry: chronic cutaneous ulcer and burn wounds - developing products for treatment. US Department of Health and Human Services, Food and Drug Administration Web site WWW document URL www.fda.gov/cber/gdlns/ ulcburn.pdf accessed on 7 April 2008 ].